Yes. Thank you. A quick reminder to everyone that the information statement and analysis discussed during this call describing the company or its affiliates, objectives, projections and estimates are forward-looking statements, and these are based on current expectations, forecasts and assumptions and are subject to risks and uncertainties, which could cause actual outcomes to materially differ. No representation of warranty, either expressed or implied, is provided in relation to the conversation and the documents provided. And the company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events or otherwise. With that, we can close the Q3 earnings call. Thank you, everyone, for joining us today. Thank you.
Questions across 7 calls
Utkarsh Gandhi
Firm not listed in source transcripts
Glenmark Pharmaceuticals Limited
Yes. So Kunal, actually, at that point, as I think we explained that what we did is we basically consolidated some of our stock points because we -- while we had the 3-tier system, we actually had -- at a -- over a period of time, we have built some ineffi ciencies in terms of how many number of stock points we had across the country. And we just thought we will consolidate some of that business. And so that was a change that happened in Q3, I mean, 18, 24 months back. I think what has happened this time, Glenn has explained, and I think we spoke about the future as well.
And Kunal, just to clarify, I mean, we can connect offline as well. But if you see the cash flow, I mean, there is part of the $700 million, right, that where we received the cash, but the P&L booking will happen in subsequent quarters. So that is sitting in other current liabilities and other noncurrent liabilities. So I mean, that's why if you adjust for that in the cash flow statement, broadly you will get to the working capital increase that we are talking about. But we can explain, we can talk it offline also in separately.
I think we had -- also had a couple of launches in Europe, Nitin, particularly, which actually got pushed to Q2. So inventory buildup was in preparation of some of these launches. So I think over the course of the next couple of quarters, the numbers will stabilize.
Thanks, Lizanne. Before we close the call, I'd just like to mention the disclaimer that discussion, information, statements and analysis made describing the company or its affiliates' objectives, projections and estimates are forward -looking statements bas ed on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially. This discussion should not be regarded by recipients as a substitute for the exercise of their own judgments, and the company undertakes no obligation to update or revise its forward -looking statements because of new information, future events or otherwise . With that, we can close the call -- the Q1 call. Thank you, everyone, for joining. Thanks, Lizanne.
We didn't get the question...
In IGI going forward.
Sorry, just to add. So typically, our second half is a little better because of the respiratory products getting further uptick. So margin profile also will accordingly be slightly better than H2.
So Kunal, the whole GLP-1 market is -- it is about, I think, INR1,000-odd crores as per IQVIA. But I mean that's not a good reference point because it's still very much under-penetrated and...
Before we end the call, we will just read out the disclaimers. The discussion during this call, including information , statements and analysis describing the Company or its affiliates, objectives, projections and estimates are forward-looking statements. These are based on current expectations, forecasts and assumptions, and are subject to risks and uncertainties, which could cause the actual outcome to differ. So, the discussion should not be regarded by recipients as a substitute for their own judgements and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. With that, we can close the call. Thank you, everyone for joining us today.
Thanks, Lizanne. Before we end the call, we'll just read out the disclaimer. The discussion during this call, including information, statements and analysis describing the company or its affiliates' objective, projections and estimates are forward-looking statements. These are based on current expectations, forecasts and assumptions, and are subject to risks and uncertainties, which could cause the actual outcomes to differ materially depending upon economic conditions, sovereign policies and other incidental factors. So all this document should not be regarded by recipients as a subject -- as a substitute for the exercise of their own their judgments. And the company undertakes no obligations to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. With that, we can close the call. Thank you, everyone, for joining us today.